AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia

First Posted Date: 2007-06-14

Last Posted Date: 2010-12-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 47

Registration Number: NCT00486265

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Iressa as Second Line Therapy in Advanced NSCLC-Asia

Phase 3

Completed

Conditions: NSCLC

Interventions: Drug: Gefitinib
Drug: Docetaxel

First Posted Date: 2007-05-24

Last Posted Date: 2012-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 163

Registration Number: NCT00478049

Locations: 🇰🇷
Research Site, Suwon, Korea, Republic of

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: exenatide
Drug: sitagliptin

First Posted Date: 2007-05-23

Last Posted Date: 2015-08-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 102

Registration Number: NCT00477581

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: AZD2171
Drug: AZD0530

First Posted Date: 2007-05-21

Last Posted Date: 2010-04-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT00475956

Locations: 🇩🇪
Research Site, Herne, Ruhr, Germany

Phase 1 Pharmacokinetics of Intravenous Nexium in Children

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: esomeprazole

First Posted Date: 2007-05-16

Last Posted Date: 2010-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 42

Registration Number: NCT00474019

Locations: 🇸🇪
Research Site, Goteborg, Sweden

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Phase 1

Terminated

Conditions: Advanced Solid Malignancies
Advanced Solid Tumors
Cancer

Interventions: Drug: AZD7762
Drug: Irinotecan

First Posted Date: 2007-05-15

Last Posted Date: 2011-02-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT00473616

Locations: 🇺🇸
Research site, Nashville, Tennessee, United States
🇺🇸
Research Site, New York, New York, United States

Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients

Phase 4

Completed

Conditions: Hypertriglyceridemia
Hyperlipoproteinemia Type IV
Hyperlipoproteinemia Type V
Hyperlipoproteinemia Type IIb
Hyperlipidemia

First Posted Date: 2007-05-15

Last Posted Date: 2010-12-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 334

Registration Number: NCT00473655

Locations: 🇲🇽
Research Site, Monterrey, Nuevo Leon, Mexico

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Phase 1

Terminated

Conditions: Lymphoma
NHL
Non-Hodgkin Lymphoma

First Posted Date: 2007-05-09

Last Posted Date: 2009-09-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 44

Registration Number: NCT00471367

Locations: 🇺🇸
Research Site, Greenville, South Carolina, United States

Phase 3/Safety & Efficacy of Esomeprazole in Infants

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease (GERD)

Interventions: Drug: Open Label Run In Esomeprazole
Drug: Double Blind Esomeprazole
Drug: Double Blind Placebo

First Posted Date: 2007-05-02

Last Posted Date: 2014-06-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 98

Registration Number: NCT00468559

Locations: 🇵🇱
Research Site, Wroclaw, Poland

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
Drug: pramlintide acetate (Symlin)
Drug: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])

First Posted Date: 2007-05-01

Last Posted Date: 2015-04-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 112

Registration Number: NCT00467649

Locations: 🇺🇸
Research Site, Spokane, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy